With box warnings

Without box warnings

Branded

Generic

4 results

kengreal
(cangrelor)
Chiesi USA, Inc.
Usage: KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to lower the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis in patients who have not received a P2Y12 platelet inhibitor and are not on a glycoprotein IIb/IIIa inhibitor.
lodoco
(Colchicine Tablets 0.5 mg)
AGEPHA Pharma USA, LLC
Usage: LODOCO is indicated for reducing the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults with established atherosclerotic disease or multiple cardiovascular disease risk factors.
lovastatin
(lovastatin)
Lupin Pharmaceuticals, Inc.
Usage: Lovastatin is indicated for lowering total and LDL cholesterol levels as part of a treatment strategy in individuals with dyslipidemia at risk for atherosclerotic vascular disease, including those with coronary heart disease and hypercholesterolemia. It is also used for primary prevention of coronary heart disease in certain populations.
nexletol
(Bempedoic Acid)
Esperion Therapeutics, Inc.
Usage: NEXLETOL is indicated for adults at risk of myocardial infarction and coronary revascularization who cannot take statins, and for reducing LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia, either as a standalone treatment or with other LDL-C lowering therapies.

Medications for Coronary Revascularisation

kengreal